As such, KIT inhibitors, are currently being investigated in clinical trials for their therapeutic potential in gastric cancer (55, 56).TXNIP functions primarily as a molecule that binds to TRX to regulate ROS and oxidative stress within cells. Here, TXNIP is linked to gastric cancer.